On May 18, 2016, the “Decisio Health†clinical introduction platform developed by the University of Texas Health Center received $4.5 million in Series B financing. "Decisio Health" was founded in April 2013 and is the target project for the commercialization of technology developed by the University of Texas Health Science Center in Houston. The technology was developed by Dr. John's research team at the Hall Translational Damage Research Center (Cetir). The initial version of the software was deployed at the Emergency Department of the Texas Medical Center in Houston and the Shock Trauma ICU Hermann Memorial Hospital. From the original research infrastructure, “Decisio Health†applied for and obtained FDA 501(k) certification for medical devices. For the first time, the US FDA 501(k) has approved the release of clinical products for the local network, and now "Decisio Health" has become the model for the role of its certified clinical decision support tools. Erythritol For Yogurts,Etherol Sugar Substitute,Polyol Erythritol,Erythritol Vegan Ningxia Eppen Biotec CO.,LTD , https://www.nxeppen.com
